Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic and environmental risk factors for chronic kidney disease.
Obrador GT, Schultheiss UT, Kretzler M, Langham RG, Nangaku M, Pecoits-Filho R, Pollock C, Rossert J, Correa-Rotter R, Stenvinkel P, Walker R, Yang CW, Fox CS, Köttgen A. Obrador GT, et al. Among authors: rossert j. Kidney Int Suppl (2011). 2017 Oct;7(2):88-106. doi: 10.1016/j.kisu.2017.07.004. Epub 2017 Sep 20. Kidney Int Suppl (2011). 2017. PMID: 30675423 Free PMC article. Review.
The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease.
Pollock C, Zuk A, Anders HJ, Ganji MR, Johnson DW, Kasiske B, Langham RG, Pecoits-Filho R, Remuzzi G, Rossert J, Suzuki Y, Tanaka T, Walker R, Yang CW, Bonventre JV. Pollock C, et al. Among authors: rossert j. Kidney Int Suppl (2011). 2017 Oct;7(2):130-137. doi: 10.1016/j.kisu.2017.07.008. Epub 2017 Sep 20. Kidney Int Suppl (2011). 2017. PMID: 30675427 Free PMC article. Review.
Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.
Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G. Levey AS, et al. Among authors: rossert j. Kidney Int. 2007 Aug;72(3):247-59. doi: 10.1038/sj.ki.5002343. Epub 2007 Jun 13. Kidney Int. 2007. PMID: 17568785 Free article.
Pure red cell aplasia induced by erythropoiesis-stimulating agents.
Pollock C, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E. Pollock C, et al. Among authors: rossert j. Clin J Am Soc Nephrol. 2008 Jan;3(1):193-9. doi: 10.2215/CJN.02440607. Clin J Am Soc Nephrol. 2008. PMID: 18178785 Review.
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P. Skali H, et al. Among authors: rossert j. Am J Kidney Dis. 2013 Feb;61(2):238-46. doi: 10.1053/j.ajkd.2012.08.043. Epub 2012 Nov 16. Am J Kidney Dis. 2013. PMID: 23159232 Clinical Trial.
Estimating glomerular filtration rate from serum creatinine and cystatin C.
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators. Inker LA, et al. N Engl J Med. 2012 Jul 5;367(1):20-9. doi: 10.1056/NEJMoa1114248. N Engl J Med. 2012. PMID: 22762315 Free PMC article.
Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Solomon SD, et al. Among authors: rossert j. N Engl J Med. 2010 Sep 16;363(12):1146-55. doi: 10.1056/NEJMoa1005109. N Engl J Med. 2010. PMID: 20843249 Free article. Clinical Trial.
153 results